Litcius/Paper detail

The Phase 3 TOURMALINE-MM2 Trial: Oral Ixazomib, Lenalidomide, and Dexamethasone (IRd) Vs Placebo-Rd for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Thierry Façon

202062nd ASH Annual Meeting and Exposition10 citations

Topics & Concepts

LenalidomideIxazomibMultiple myelomaMedicinePlaceboDexamethasoneInternal medicineOncologySurgeryPathologyAlternative medicineCarfilzomibMultiple Myeloma Research and TreatmentsQuinazolinone synthesis and applicationsMulticomponent Synthesis of Heterocycles
The Phase 3 TOURMALINE-MM2 Trial: Oral Ixazomib, Lenalidomide, and Dexamethasone (IRd) Vs Placebo-Rd for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) | Litcius